In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

Prilenia Will Retain Full Rights To Pridopidine In Other Major Markets

 
• By Sushmita Panda
  
Therapeutic research
Pridopidine is a potent and highly selective oral sigma-1 receptor (S1R) agonist designed to modulate critical neuroprotective pathways. (Shutterstock)

More from Deals

More from Therapy Areas